.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
CRASH-2 was a large randomised placebo-controlled trial assessing early tranexamic acid in adult trauma patients with, or at risk of, significant bleeding. More than 20,000 patients from 274 hospitals in 40 countries were randomised within eight hours of injury to tranexamic acid or placebo. The study established that an antifibrinolytic treatment can influence survival after traumatic haemorrhage, with the greatest benefit associated with early administration. The trial also found no major excess of vascular occlusive events attributable to tranexamic acid. For clinicians, timing is central. Tranexamic acid is most useful when given early in patients who are bleeding or at substantial risk of bleeding, alongside definitive haemorrhage control and blood-component resuscitation. It is not a substitute for surgery, interventional radiology or correction of shock. The trial directly supports CritiCARE's focus on trauma-related coagulopathy and haemorrhage control. It is also a good example of how a simple, inexpensive intervention can have global relevance when delivered promptly. The practical takeaway is to incorporate tranexamic acid into an established trauma haemorrhage pathway rather than treating it as an isolated medication decision.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
CRASH-2 was a large randomised placebo-controlled trial assessing early tranexamic acid in adult trauma patients with, or at risk of, significant bleeding. More than 20,000 patients from 274 hospitals in 40 countries were randomised within eight hours of injury to tranexamic acid or placebo. The study established that an antifibrinolytic treatment can influence survival after traumatic haemorrhage, with the greatest benefit associated with early administration. The trial also found no major excess of vascular occlusive events attributable to tranexamic acid. For clinicians, timing is central. Tranexamic acid is most useful when given early in patients who are bleeding or at substantial risk of bleeding, alongside definitive haemorrhage control and blood-component resuscitation. It is not a substitute for surgery, interventional radiology or correction of shock. The trial directly supports CritiCARE's focus on trauma-related coagulopathy and haemorrhage control. It is also a good example of how a simple, inexpensive intervention can have global relevance when delivered promptly. The practical takeaway is to incorporate tranexamic acid into an established trauma haemorrhage pathway rather than treating it as an isolated medication decision.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
